1580-50-3

Basic information

• Product Name: 2-(4-fluorophenyl)-5-phenyl-1,3,4-oxadiazole
• Synonyms: 2-(4-Fluorophenyl)-5-phenyl-1,3,4-oxadiazole
• CAS NO: 1580-50-3
• Molecular Formula: C₁₄H₉FN₂O
• Molecular Weight: 240.2325
• EINECS: 216-425-1
• Mol File: 1580-50-3.mol
• Article Data: 23

Chemical Properties

• Boiling Point: 374.2°C at 760 mmHg
• Flash Point: 180.1°C
• Density: 1.241g/cm³
• Vapor Pressure: 1.82E-05mmHg at 25°C
• Refractive Index: 1.574
• CAS DataBase Reference: 2-(4-fluorophenyl)-5-phenyl-1,3,4-oxadiazole(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-fluorophenyl)-5-phenyl-1,3,4-oxadiazole(1580-50-3)
• EPA Substance Registry System: 2-(4-fluorophenyl)-5-phenyl-1,3,4-oxadiazole(1580-50-3)

Safety Data

• Hazardous Substances Data: 1580-50-3(Hazardous Substances Data)

Usage

General Description

2-(4-fluorophenyl)-5-phenyl-1,3,4-oxadiazole, also known as fluorophenyl oxadiazole, is a chemical compound with the molecular formula C14H9FN2O. It belongs to the oxadiazole class and contains a fluorophenyl and phenyl group. 2-(4-fluorophenyl)-5-phenyl-1,3,4-oxadiazole has shown potential pharmacological activity, including as an anti-inflammatory and analgesic agent. It is also used in the field of organic electronics and material science, where it exhibits fluorescence properties. The synthesis and study of 2-(4-fluorophenyl)-5-phenyl-1,3,4-oxadiazole continue to be of interest in various scientific and industrial applications.

Upstream product

• 2251-76-5 2-(4-fluorophenyl)-2-oxoacetic acid 
• 613-94-5 benzoic acid hydrazide 
• 456-06-4 4-fluorobenzoyl hydrazide 
• 611-74-5 N,N-dimethylbenzamide 
• 119072-55-8 tert-butylisonitrile 
• 352-34-1 4-fluoro-1-iodobenzene 
• 591-50-4 iodobenzene 
• 459-57-4 4-fluorobenzaldehyde 
• 18039-42-4 5-phenyl-2H-1,2,3,4-tetrazole 
• 50907-21-6 5-(4-fluorophenyl)-2H-tetrazole 
• 100-52-7 benzaldehyde 
• 456-22-4 4-Fluorobenzoic acid 
• 403-33-8 methyl 4-flurobenzoate 
• 115504-61-5 N'-[(4-fluorophenyl)methylidene]benzeneacylhydrazone 

Downstream Products

• 950839-30-2 2-(4-(9H-carbazol-9-yl)phenyl)-5-phenyl-1,3,4-oxadiazole 

Relevant articles and documents

The preparation, characterization and catalytic activity of Ni NPs supported on porous alginate-g-poly(p-styrene sulfonamide-co-acrylamide)

Herein, we report the synthesis of nickel nanoparticles under mild conditions using porous alginate-g-poly(p-styrene sulfonamide-co-acrylamide) as a protecting/stabilizing agent and sodium borohydride as a reducing agent. The porous cross-linked polymeric support was preparedviacombining the use of sol-gel, nanocasting, and crosslinking techniques, in which thep-styrene sulfonamide monomer (PSSA) andN,N′-methylene-bis (acrylamide) (MBA) cross-linker underwent copolymerization on the surface of sodium alginate in the presence of a SiO2nanoparticle (NP) template (Alg-PSSA-co-ACA). The prepared catalyst (Alg-PSSA-co-ACA@Ni) showed high catalytic activity for the one-step synthesis of 1,3,4-oxadiazoles from the reaction of hydrazides and aryl iodides through isocyanide insertion/cyclization.

TiCl4 mediated facile synthesis of 1,3,4-oxadiazoles and 1,3,4-thiadiazoles

An efficient method for the synthesis of 2,5-disubstituted 1,3,4-oxadiazoles and 1,3,4-thiadiazoles has been developed. Various hydrazides or thionyl hydrazides readily react with DMA derivatives in the presence of TiCl4 as a catalyst to afford the desired products. This protocol provides a simple and economical procedure that affords the target products with good yields and wide substrate scope.

Rescuing the CFTR protein function: Introducing 1,3,4-oxadiazoles as translational readthrough inducing drugs

Nonsense mutations in the CFTR gene prematurely terminate translation of the CFTR mRNA leading to the production of a truncated protein that lacks normal function causing a more severe form of the cystic fibrosis (CF) disease. About 10% of patients affected by CF show a nonsense mutation. A potential treatment of this alteration is to promote translational readthrough of premature termination codons (PTCs) by Translational Readthrough Inducing Drugs (TRIDs) such as PTC124. In this context we aimed to compare the activity of PTC124 with analogues differing in the heteroatoms position in the central heterocyclic core. By a validated protocol consisting of computational screening, synthesis and biological tests we identified a new small molecule (NV2445) with 1,3,4-oxadiazole core showing a high readthrough activity. Moreover, we evaluated the CFTR functionality after NV2445 treatment in CF model systems and in cells expressing a nonsense-CFTR-mRNA. Finally, we studied the supramolecular interactions between TRIDs and CFTR-mRNA to assess the biological target/mechanism and compared the predicted ADME properties of NV2445 and PTC124.